Background: Directly measured low density lipoprotein cholesterol (DLDLC) has been reported to be more accu rate than calculated low density lipoprotein cholesterol (CLDLC) using the Friedewald equation. However, some limitations of DLDLC have been reported. In this study, we evaluated differences between CLDLC and DLDLC mea sured using HiSens reagents. Methods: Data were collected from 582 persons undergoing routine physical examinations at a general hospital. LDLC measurements were made directly or estimated using the Friedewald formula, and were classified according to the National Cholesterol Education Program's Adult Treatment Panel III guidelines. The relationship between these differences and other clinically relevant factors, such as triglyceride (TG) levels, were examined using multi ple logistic regression analysis. Results: The DLDLC and CLDLC were strongly correlated according to simple linear regression analysis (r = 0.917, P < 0.001) but the mean difference between measurements was 11.0 ± 15.3 (62 to 90.5) mg/dL (P < 0.001). For more than 10 mg/dL of their absolute differences, the DLDLC was typically lower than the CLDLC. The highest dis crepancies in LDLC measurements occurred when LDLC was more than 160 mg/dL and less than 190 mg/dL. Dif ferences in LDLC measurements were prone to striking negative and positive biases dependent on CLDLC and TG concentrations, respectively (all r > 0.5). Conclusion: Unlike other studies, DLDLC was significantly lower than CLDLC and the large differences in LDLC concentrations were not dependent on TG concentration. Our work suggests that verification of DLDLC accuracy is needed and differences in LDLC measurements should be accounted for in making clinical decisions.
INTRODUCTION
Low density lipoprotein cholesterol (LDLC) is a major risk fac tor in atherosclerosis and coronary heart disease (CHD) and a main target for diagnosis and treatment of hyperlipidemia. 1) The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines for hyperlipidemia, which are the most commonly referred to guidelines, were recently updated to ATP IV. 2, 3) These guidelines suggest that the calcu lated LDLC (CLDLC), assessed using the Friedewald formula, should be the primary lipid target for CHD risk reduction. 4) The reference method for measuring LDLC is beta quantification. 1, 5) Friedewaldestimated LDLC is used in clinical practice because it is more convenient and less expensive than the more compli cated and timeconsuming beta quantification. 6) However, the CLDLC is inaccurate when triglycerides (TG) are greater than 400 mg/dL, which occurs in dysbetalipoproteinemia and hy perlipoproteinemia secondary to diabetes, as well as when pa tients have not fasted.
710)
Because of the limitations of the Friedewald calculation, ho mogenous methods capable of full automation have been in troduced for directly quantifying LDLC.
11) The direct LDLC (DL DLC) quantification produces variable results due to differenc es in the homogenization method and reagents. The Choles terol Reference Method Laboratory Network (CRMLN) of the Centers for Disease Control of the United States certifies manu facturers of clinical diagnostic products and offers a list of vali dated reagents for accurate LDLC quantification. 12) However, there are hospitals using the direct LDLC assay with compo nents not listed by the CRMLM, which has led to questions re garding the assay's validity. Therefore, we evaluated assay per formance using the domestic HiSens reagent in comparison to the LDLC calculated using the Friedewald equation.
METHODS

Population
Our population consisted of 582 subjects who visited the health promotion center of the KEPCO Medical Center in Seoul, Repu lic of Korea for general health checkups between November 2012 and February 2013. Lipid profiles in the 12hour fasting state, among other values, were analyzed (Table 1 ). All data were obtained by retrospective review of electronic medical re cords. The study protocol was reviewed and approved by the institutional review board of the KEPCO Medical Center (No. HIRB2014002).
Lipid Measurement
CLDLC was calculated using the Friedewald equation (LDLC = [total cholesterol (TC)][high density lipoprotein cholesterol (HDLC)]TG/5). 13) TC and TG were measured using the AU CHO LESTEROL A reagent and the AU TRIGLYCERIDE agent (Beck man Coulter Inc., Galway, Ireland). DLDLC and HDLC were measured directly using the HiSens LDLC and HiSens HDLC reagents (HBI Co. Ltd., Anyang, Korea), respectively. All lipid profiles except CLDLC were measured using the Olympus AU 2700 chemistry analyzer (Beckman Coulter Inc., Fullerton, CA, USA).
To verify the accuracy of DLDLC quantification using HiSens reagents, 30 samples with TG levels less than 400 mg/dL were random ly collected for quality control. DLDLC concentrations were compared to concentrations measured using the Beck man Coulter 5821 analyzer and dedicated reagent (BCDR) us ing simple regression analysis. Values are presented as mean ± SD (range) unless otherwise indicated. BP, blood pressure; CLDLC, calculated low density lipoprotein cholesterol; DLDLC, direct low density lipoprotein cholesterol; baPWV, brachial-ankle aortic pulse wave velocity. *Arterial stiffness is graded according to the baPWV: 1 (soft, baPWV < 900 cm/s), 2 (hardish, baPWV < 1,600 cm/s), 3 (hard, baPWV < 2,500 cm/s). †
The value is presented as the median (range). ‡ Evaluated by brain and carotid magnetic resonance and angiography. § The calcium score and coronary artery stenosis were evaluated by electron-beam computed tomography and coronary computed tomography angiogram, respectively.
Statistical Analysis
The means ± standard deviations and medians for continuous variables and proportions (percentiles) for categorical variables were calculated for all descriptive statistics. The differences in LDLC concentrations were analyzed by two sample paired t tests, linear regression analysis using Pearson's correlation co efficients, and the multiple logistic regression analysis. A Pval ue of less than 0.05 was considered statistically significant. All statistical analyses were performed with the statistical software package PASW SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The population baseline characteristics are listed in Table 1 . The mean of DLDLC and CLDLC were 116.6 ± 28.6 mg/dL (range, 44.3 to 209.5 mg/dL) and 127.5 ± 36.4 mg/dL (range, 28 to 249 mg/dL), respectively. The DLDLC and CLDLC values were strong ly correlated according to simple linear regression analysis (Pear son's correlation coefficient r=0.917, P<0.001) (Figure 1 ). How ever, the mean difference between DLDLC and CLDLC was 11.0 ± 15.3 mg/dL (range, 62 to 90.5 mg/dL), and the DLDLC was significantly lower than CLDLC (P < 0.001). For 61.9% of subjects, the absolute difference in LDLC measurements was more than 10 mg/dL, and for 86.9% of these subjects, the DLD LCs were lower than the CLDLCs. For 30.9% of subjects, the absolute difference in LDLC measurements was more than 20 mg/dL, and for 87.8% of these subjects, the DLDLCs were lower than the CLDLCs. The fraction of subjects with the absolute dif ference, more than 20 mg/dL of LDLC measurements increased dependent to DLDLC concentrations (Figure 2) . Simple linear regression analysis suggested that the difference in LDLC mea surements was negatively correlated with DLDLC and CLDLC ( Figure 3 ). The categorical concordance of LDLC measurements according to the NCEP ATP III guidelines was only high in LDLC concentrations less than 70 mg/dL and 190 mg/dL or more (Ta ble 2). The differences in LDLC measurements were positively correlated with TG concentration (r = 0.557, P < 0.001) ( Figure  3 ). The fraction of subjects with the absolute difference, more than 10 mg/dL of LDLC measurements decreased dependent to TG concentrations except for 400 mg/dL or more unlike DL DLC (Figure 2) .
Among other factors, TC and HDLC were negatively corre lated with the difference in LDLC measurements, while glucose was slightly positively correlated (simple linear regression) (Fig  ure 3) . The multiple logistic regression analysis showed that high glucose, glomerular filtration rate, and high CLDLC were sig nificantly associated with high LDL differences (Table 3) . Lipid lowering medications were also associated with high differenc es in LDL measurements, but the statistical significance was slightly low (P = 0.054). Additionally, current smoking, coronary calcium score, high TC, and high TG were significantly associ ated with very high LDL differences, but the goodness of fit for the logistic regression was slightly low (P = 0.047, estimated by the Hosmer-Lemeshow test). The HiSens DLDLC concentra tions were strongly correlated the with Beckman Coulter DLD LC measurements (simple linear regression, r≥0.975) (Figure 4 ).
DISCUSSION
We evaluated the differences in LDLC concentrations measur ed by the HiSens reagent and those calculated using the Frie dewald equation. According to previous studies, calculations of LDLC based on the Friedewald equation (CLDLC) correlated well with quantification of LDLC (DLDLC), but generally, CLD LC was underestimated in comparison to DLDLC. 1,4,6,1417) Our results suggest that CLDLC generally correlated with DLDLC, but CLDLC was significantly higher than DLDLC, with a mean difference of 11.0 ± 15.3 mg/dL. The DLDLC measured using the HiSens reagent was consistent with measurements made using BCDR (the mean difference was about 2.9 mg/dL, P < 0.001), ensuring quality control. The highest discrepancies (62.5%) in LDLC occurred when the LDLC was higher than 160 mg/dL, but less than 190 mg/dL. These results suggest the pos sibility of improper management of patients with hyperlipid emia, including the general population without CHD risk, ac cording to the ATP III or IV guidelines. Large differences in LDLC measurements ( ≥ 10 mg/dL) were observed in more than half of the participants with serum TG levels less than 200 mg/dL, which is inconsistent with other stu dies.
14,18) Serum TG levels of more than 400 mg/dL were associ ated with very large differences in LDLC measurements ( ≥ 20 mg/dL). Here we found that HDLC, obesity, diabetes, and gen der, among the values reported by Choi et al. 14) were not signifi cantly associated with large differences in LDLC measurements. Diabetes and lipid lowering medications seemed to influence these results, but these were factors for a minority of patients.
Although the HiSens reagent for DLDLC measurements show ed good correlation with other domestic reagent in a study, 19) results were inconsistent with other studies, particularly in that the CLDLC was higher than DLDLC and the large differences in LDLC measurements were not generally dependent on TG concentrations, although high TG produced a positive bias. These discrepancies can be attributed to inaccuracies in either CLDLC or DLDLC estimations. It is known that the DLDLC procedure is more precise and accurate than the CLDLC, cal culated using three analytical variables (TC, TG, and HD LC). 11, 20) However, some DLDLC measurements have been limited be cause of cholesterol rich very low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) for patients with di abetes or type III hyperlipidemia. 21, 22) The ultracentrifugation as a reference method measures LDL including IDL, and lipo protein(a), which are all atherogenic particles. However, direct methods for measuring such particles are influenced by the VLDLC/TG ratio, the size of the LDL particle, and the wrong assignment of the calibrator value, etc. When the VLDL is rich in TG , direct methods tend to underestimate LDLC 22) and have been reported to be less reactive with lipoproteins, which con tains small, dense LDL and/or lipoprotein(a). 23) High TG levels can cause low CLDLC if the TG ratio is not adjusted in the Friedewald equation. 21, 22, 24) Both LDLC mea surements can be negatively biased by high TG and the abso lute difference between them can be reduced. Although the two DLDLC measurements were consistent with each other, neither of the two reagents used for our DLDLC measurements were verified by CRMLN, warranting further studies. There were several limitations to the methodologies present ed here. We did not compare the results with the reference me thod (beta quantification) or verified direct methods by CRMLN, for measuring LDLC. This study was crosssectional and includ ed healthy participants from one center. However, we found that there were differences between DLDLC and CLDLC, which could have a significant impact on clinical decisions.
In conclusion, DLDLC measurements were significantly low er than CLDLC measurements, and the differences between LDLC measurements were prone to negative and positive bias es that were dependent on CLDLC and TG concentrations, re spectively. In contrast to other studies, large differences in LDLC measurements were not dependent on TG concentrations. Our work suggests that verification of DLDLC accuracy is needed and differences in LDLC measurements should be accounted for in making clinical decisions.
